Differential Regulation of Human Platelet Responses by cGMP Inhibited and Stimulated cAMP Phosphodiesterases^[*]

Summary

Platelets contain two cAMP phosphodiesterases (PDEs) which regulate intracellular cAMP levels, cGMP-inhibited cAMP PDE (PDE3A) and cGMP-stimulated PDE (PDE2A). Using the PDE3 inhibitor, milrinone and the PDE2 inhibitor, erythro-9-(2-hydroxyl-3-nonyl)adenine (EHNA), we have explored the contribution of each PDE to the regulation of platelet function. Inhibition of PDE2 resulted in higher levels of intracellular cAMP than inhibition of PDE3A suggesting this PDE may be the more important regulator of cAMP in human platelets. However, a concentration-dependent inhibition of agonist-induced aggregation was observed with milrinone while little effect was seen with EHNA. In addition, we observed a concentration-dependent inhibition in the increase of intracellular Ca2+ with PDE3 inhibition and significantly less with PDE2 inhibition. PDE3 inhibition also resulted in a concentration-dependent increase in cAMP-mediated phosphorylation of the vasodilator-stimulated phospho-protein (VASP) whereas there was no significant increase with PDE2 inhibition. In each of these experiments, synergism was noted with the combination of milrinone and EHNA. These results suggest that cAMP pools may be localized and the various PDEs regulate specific pools. These data also suggest that inhibitors of PDE3A may be more effective antiplatelet agents.

Keywords

Phosphodiesterases - platelets - cAMP - milrinone - EHNA

^* Supported by: a grant from the Southeastern Pennsylvania Affiliate of the American Heart Association

• References

• 1 Salzman EW, Weisenberger H. Role of cyclic AMP in platelet function. Adv Cyclic Nucleotide Res 1972; 01: 231-47.
• 2 Sheth SB, Colman RW. Regulatory and catalytic domains of platelet cAMP phosphodiesterases: targets for drug design. Semin Hematol 1995; 32 (02) 110-9.
• 3 Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995; 75 (04) 725-48.
• 4 Grant PG, Mannarino AF, Colman RW. Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from the cytosol of human platelets. Thromb Res 1990; 59 (01) 105-19.
• 5 Shakur Y, Takeda K, Kenan Y, Yu ZX, Rena G, Brandt D, Houslay MD, Degerman E, Ferrans VJ, Manganiello VC. Membrane localization of cyclic nucleotide phosphodiesterase 3 (PDE3). Two N-Terminal Domains are required for the efficient targeting to, and association of, PDE3 with endoplasmic reticulum. [In Process Citation]. J Biol Chem 2000; 275 (49) 38749-61.
• 6 Verde I, Pahlke G, Salanova M, Zhang G, Wang S, Coletti D, Onuffer J, Jin SL, Conti M. Myomegalin is a novel protein of the golgi/centrosome that interacts with a cyclic nucleotide phosphodiesterase. J Biol Chem 2001; 276 (14) 11189-98.
• 7 Halbrugge M, Friedrich C, Eigenthaler M, Schanzenbacher P, Walter U. Stoichiometric and reversible phosphorylation of a 46-kDa protein in human platelets in response to cGMP-and cAMP-elevating vasodilators. J Biol Chem 1990; 265 (06) 3088-93.
• 8 Smith JB, Dangelmaier C, Selak MA, Daniel JL. Facile platelet adhesion to collagen requires metabolic energy and actin polymerization and evokes intracellular free calcium mobilization. J Cell Biochem 1991; 47 (01) 54-61.
• 9 Smolenski A, Bachmann C, Reinhard K, Honig-Liedl P, Jarchau T, Hoschuetzky H, Walter U. Analysis and regulation of vasodilator-stimulated phosphoprotein serine 239 phosphorylation in vitro and in intact cells using a phosphospecific monoclonal antibody. J Biol Chem 1998; 273 (32) 20029-35.
• 10 Schwarz UR, Geiger J, Walter U, Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets – definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost 1999; 82 (03) 1145-52.
• 11 Butt E, Abel K, Krieger M, Palm D, Hoppe V, Hoppe J, Walter U. cAMPand cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets. J Biol Chem 1994; 269 (20) 14509-17.
• 12 Eigenthaler M, Nolte C, Halbrugge M, Walter U. Concentration and regulation of cyclic nucleotides, cyclic-nucleotide-dependent protein kinases and one of their major substrates in human platelets. Estimating the rate of cAMP-regulated and cGMP-regulated protein phosphorylation in intact cells. Eur J Biochem 1992; 205 (02) 471-81.
• 13 Grant PG, Mannarino AF, Colman RW. cAMP-mediated phosphorylation of the low-Km cAMP phosphodiesterase markedly stimulates its catalytic activity. Proc Natl Acad Sci USA 1988; 85 (23) 9071-5.
• 14 Weishaar RE, Kobylarz-Singer DC, Kaplan HR. Subclasses of cyclic AMP phosphodiesterase in cardiac muscle. J Mol Cell Cardiol 1987; 19 (10) 1025-36.
• 15 Weishaar RE, Kobylarz-Singer DC, Quade MM, Steffen RP, Kaplan HR. Multiple molecular forms of phosphodiesterase and the regulation of cardiac muscle contractility. J Cyclic Nucleotide Protein Phosphor Res 1986; 11 (07) 513-27.
• 16 Weishaar RE, Burrows SD, Kobylarz DC, Quade MM, Evans DB. Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents. Biochem Pharmacol 1986; 35 (05) 787-800.
• 17 Suttorp N, Weber U, Welsch T, Schudt C. Role of phosphodiesterases in the regulation of endothelial permeability in vitro. J Clin Invest 1993; 91 (04) 1421-8.
• 18 Honerjager P. Pharmacology of positive inotropic phosphodiesterase III inhibitors. Eur Heart J 1989; 10 (Suppl C): 25-31.
• 19 Roevens P, de Chaffoy de Courcelles D. Cyclic AMP-phosphodiesterase IIIA1 inhibitors decrease cytosolic Ca2+ concentration and increase the Ca2+ content of intracellular storage sites in human platelets. Biochem Pharmacol 1993; 45 (11) 2279-82.
• 20 Hidaka H, Endo T. Selective inhibitors of three forms of cyclic nucleotide phosphodiesterase – basic and potential clinical applications. Adv Cyclic Nucleotide Protein Phosphorylation Res 1984; 16: 245-59.
• 21 Alvarez R, Taylor A, Fazzari JJ, Jacobs JR. Regulation of cyclic AMP metabolism in human platelets Sequential activation of adenylate cyclase and cyclic AMP phosphodiesterase by prostaglandins. Mol Pharmacol 1981; 20 (02) 302-9.
• 22 Dickinson NT, Jang EK, Haslam RJ. Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation. Biochem J 1997; 323 (Pt 2): 371-7.
• 23 Tani T, Sakurai K, Kimura Y, Ishikawa T, Hidaka H. Pharmacological manipulation of tissue cyclic AMP by inhibitors. Effects of phosphodiesterase inhibitors on the functions of platelets and vascular endothelial cells. Adv Second Messenger Phosphoprotein Res 1992; 25: 215-27.
• 24 Anfossi G, Massucco P, Piretto V, Mularoni E, Cavalot F, Mattiello L, Trovati M. Interplay between milrinone and adenosine in the inhibition of human platelet response. Gen Pharmacol 1996; 27 (07) 1149-54.
• 25 Haslam RJ, Rosson GM. Effects of adenosine on levels of adenosine cyclic 3’,5’-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation. Mol Pharmacol 1975; 11 (05) 528-44.
• 26 Jurevicius J, Fischmeister R. cAMP compartmentation is responsible for a local activation of cardiac Ca2+ channels by beta-adrenergic agonists. Proc Natl Acad Sci USA 1996; 93 (01) 295-9.
• 27 Mery PF, Pavoine C, Pecker F, Fischmeister R. Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes. Mol Pharmacol 1995; 48 (01) 121-30.
• 28 Rivet-Bastide M, Vandecasteele G, Hatem S, Verde I, Benardeau A, Mercadier JJ, Fischmeister R. cGMP-stimulated cyclic nucleotide phosphodiesterase regulates the basal calcium current in human atrial myocytes. J Clin Invest 1997; 99 (11) 2710-8.
• 29 Siegl AM, Daly JW, Smith JB. Inhibition of aggregation and stimulation of cyclic AMP generation in intact human platelets by the diterpene forskolin. Mol Pharmacol 1982; 21 (03) 680-7.
• 30 Seiler S, Gillespie E, Arnold AJ, Brassard CL, Meanwell NA, Fleming JS. Imidazoquinoline derivatives: potent inhibitors of platelet cAMP phospho-diesterase which elevate cAMP levels and activate protein kinase in platelets. Thromb Res 1991; 62 1-2 31-42.
• 31 Banner KH, Moriggi E, Da Ros B, Schioppacassi G, Semeraro C, Page CP. The effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti-asthma drugs on inflammatory cell activation. Br J Pharmacol 1996; 119 (06) 1255-61.
• 32 Pooley L, Shakur Y, Rena G, Houslay MD. Intracellular localization of the PDE4A cAMP-specific phosphodiesterase splice variant RD1 (RNPDE4A1A) in stably transfected human thyroid carcinoma FTC cell lines. Biochem J 1997; 321 (Pt 1): 177-85.
• 33 Huston E, Beard M, McCallum F, Pyne NJ, Vandenabeele P, Scotland G, Houslay MD. The cAMP-specific phosphodiesterase PDE4A5 is cleaved downstream of its SH3-interaction domain by caspase-3: consequences for altered intracellular distribution. J Biol Chem 2000; 275 (36) 28063-74.
• 34 Chini CC, Grande JP, Chini EN, Dousa TP. Compartmentalization of cAMP signaling in mesangial cells by phosphodiesterase isozymes PDE3 and PDE4. Regulation of superoxidation and mitogenesis. J Biol Chem 1997; 272 (15) 9854-9.
• 35 Houslay MD, Milligan G. Tailoring cAMP-signalling responses through isoform multiplicity. Trends Biochem Sci 1997; 22 (06) 217-24.
• 36 Rubin CS. A kinase anchor proteins and the intracellular targeting of signals carried by cyclic AMP. Biochim Biophys Acta 1994; 1224 (03) 467-79.
• 37 Houslay MD, Sullivan M, Bolger GB. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting antiinflammatory and antidepressant actions. Adv Pharmacol 1998; 44: 225-342.
• 38 Rich TC, Fagan KA, Nakata H, Schaack J, Cooper DM, Karpen JW. Cyclic nucleotide-gated channels colocalize with adenylyl cyclase in regions of restricted cAMP diffusion. J Gen Physiol 2000; 116 (02) 147-61.
• 39 Rich TC, Fagan KA, Tse TE, Schaack J, Cooper DM, Karpen JW. A uniform extracellular stimulus triggers distinct cAMP signals in different compartments of a simple cell. Proc Natl Acad Sci USA 2001; 98 (23) 13049-54.
• 40 Sheth SB, Brennan KJ, Biradavolu R, Colman RW. Isolation and regulation of the cGMP-inhibited cAMP phosphodiesterase in human erythroleukemia cells. Thromb Haemost 1997; 77 (01) 155-62.
• 41 Maurice DH, Haslam RJ. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol 1990; 37 (05) 671-81.
• 42 Riondino S, Gazzaniga PP, Pulcinelli FM. Evidence for platelet alphaIIb beta3 activation despite elevated cytosolic cAMP. Thromb Haemost 2001; 85 (02) 320-5.